UNSPSC 51294410: Tebatizole

This classification denotes an antidepressant agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P0S37156TW. European Medicines Agency schedules Tebatizole in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10853MIG. Tebatizole generally arises in the molecular formula C12H21N3S.

UNSPSC 51294410 Tebatizole, a Commodity code, nominally designates a specific antifungal pharmaceutical active ingredient, but recent state and local solicitations tagged with this code show little alignment with tebatizole procurement itself. Instead, the code appears in opportunities for broader pharmaceutical and health-system products — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with over-the-counter products. State and local buying under this code reflects health departments, pharmacy benefits programs, and cooperative purchasing alliances sourcing emergency medical supplies, community health products, and formulary pharmaceuticals through competitive bid and RFP processes. The issuing bodies span county health systems (Seminole County, Florida), state human services commissions (Texas HHS), and multistate cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, serving participating states including Oregon).

Recent activity concentrates in Florida and Texas, with multistate cooperative contracting through Minnesota administration. Seminole County, Florida issued IFB 60459723LAS in June 2026 (due July 26, 2023 — note date inconsistency in source) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a two-year term and one-year renewal option. The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026 to gather market intelligence on direct-to-manufacturer prescription programs and vendor capabilities for self-insured pharmacy contracting. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with contract effectiveness July 1, 2026 and evaluation weighted heavily on price competitiveness (75 percent). The code shows active pharmaceutical procurement activity across health systems and cooperative purchasing, though the tebatizole code appears to be a tagging artifact rather than reflecting actual tebatizole-specific demand.